BR112015021480A2 - soluções de hidromorfona intratecais tendo estabi-lidade melhorada - Google Patents

soluções de hidromorfona intratecais tendo estabi-lidade melhorada

Info

Publication number
BR112015021480A2
BR112015021480A2 BR112015021480A BR112015021480A BR112015021480A2 BR 112015021480 A2 BR112015021480 A2 BR 112015021480A2 BR 112015021480 A BR112015021480 A BR 112015021480A BR 112015021480 A BR112015021480 A BR 112015021480A BR 112015021480 A2 BR112015021480 A2 BR 112015021480A2
Authority
BR
Brazil
Prior art keywords
improved stability
intrathecal
hydromorphone
solutions
hydromorphone solutions
Prior art date
Application number
BR112015021480A
Other languages
English (en)
Inventor
J Foster John
R Prentice Thomas
Original Assignee
Mallinckrodt Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Llc filed Critical Mallinckrodt Llc
Publication of BR112015021480A2 publication Critical patent/BR112015021480A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo soluções de hidromorfona intratecais tendo estabilidade melhorada a presente invenção refere-se geralmente a uma solução farmacêutica compreendendo hidromorfona ou um sal farmaceuticamente aceitável da mesma que é substancialmente livre de tampão e, opcionalmente, um ou mais outros aditivos. o sal farmaceuticamente aceitável pode ser cloridrato de hidromorfona. também são descritos métodos para fabricar e usar a solução.
BR112015021480A 2013-03-06 2013-09-06 soluções de hidromorfona intratecais tendo estabi-lidade melhorada BR112015021480A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/787,042 US9155734B2 (en) 2012-03-07 2013-03-06 Stability of hydromorphone hydrochloride solutions
PCT/US2013/058519 WO2014137385A1 (en) 2013-03-06 2013-09-06 Intrathecal hydromorphone solutions having improved stability

Publications (1)

Publication Number Publication Date
BR112015021480A2 true BR112015021480A2 (pt) 2017-07-18

Family

ID=49231622

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021480A BR112015021480A2 (pt) 2013-03-06 2013-09-06 soluções de hidromorfona intratecais tendo estabi-lidade melhorada

Country Status (10)

Country Link
US (3) US9155734B2 (pt)
EP (1) EP2964188A1 (pt)
JP (1) JP6190475B2 (pt)
KR (1) KR101892797B1 (pt)
CN (1) CN105073095A (pt)
BR (1) BR112015021480A2 (pt)
CA (1) CA2902823C (pt)
IL (1) IL240910B (pt)
MX (1) MX2015011178A (pt)
WO (1) WO2014137385A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2884406B1 (fr) 2005-04-14 2008-10-17 Memometal Technologies Soc Par Dispositif d'osteosynthese intramedullaire de deux parties d'os, notamment de la main et/ou du pied
FR2935601B1 (fr) 2008-09-09 2010-10-01 Memometal Technologies Implant intramedullaire resorbable entre deux os ou deux fragments osseux
US9155734B2 (en) 2012-03-07 2015-10-13 Mallinckrodt Llc Stability of hydromorphone hydrochloride solutions
CN107028968B (zh) * 2016-02-03 2020-12-04 江苏恒瑞医药股份有限公司 一种含有葡萄糖醛酸吗啡或其可药用盐的药物组合物
EP3251621B1 (en) 2016-06-03 2021-01-20 Stryker European Holdings I, LLC Intramedullary implant
US20230301986A1 (en) * 2022-03-23 2023-09-28 Hikma Pharmaceuticals Usa Inc. Ready-to-administer hydromorphone formulations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7244696A (en) 1995-09-29 1997-04-17 Lam Pharmaceuticals Inc. Sustained release delivery system and long acting narcotic analgesics and antagonists
ATE402937T1 (de) 1999-11-09 2008-08-15 Abbott Lab Hydromorphinone and hydrocodeinone compositions and methods for their synthesis
WO2003070175A2 (en) 2002-02-15 2003-08-28 Howard Brooks-Korn Use of opioid compound to treat a neurologic or neurogenic disorder
US20040102476A1 (en) 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
EP1689401A1 (en) * 2003-10-02 2006-08-16 Elan Pharmaceuticals, Inc. Method for reducing pain
AU2006236379A1 (en) * 2005-04-18 2006-10-26 Noramaco Inc. Hydromorphone polymorphs
BRPI0503734A (pt) * 2005-08-23 2007-04-27 Cristalia Prod Quimicos Farm composição farmacêutica na forma de solução injetável de morfina pronta para uso e forma de dosagem unitária de morfina para administração epidural ou intratecal
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
SI2341899T1 (sl) * 2008-09-24 2015-04-30 Evonik Roehm Gmbh Od pH odvisen opioidni farmacevtski sestavek z nadzorovanim sproščanjem z odpornostjo na vpliv etanola
AU2010218424B2 (en) 2009-02-26 2014-02-13 Techno Guard Co., Ltd. Narcotic emulsion formulations for treatment of cancer pain
US9458536B2 (en) 2009-07-02 2016-10-04 Sio2 Medical Products, Inc. PECVD coating methods for capped syringes, cartridges and other articles
US8461171B2 (en) 2010-02-09 2013-06-11 QRxPharma Ltd. Hybrid opioid compounds and compositions
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
EP2446882B8 (de) 2010-10-28 2014-02-12 Acino Pharma AG Arzneimittel mit dem Wirkstoff Hydromorphon mit verbesserter Lagerstabilität
AU2011336467A1 (en) 2010-12-01 2013-07-04 Spinal Modulation, Inc. Agent delivery systems for selective neuromodulation
WO2013063263A1 (en) 2011-10-25 2013-05-02 Lycus Llc Pharmaceutical compositions for treating pain
EP2776603B1 (en) 2011-11-11 2019-03-06 SiO2 Medical Products, Inc. PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS
EP2822535A1 (en) 2012-03-07 2015-01-14 Mallinckrodt LLC Improved stability of hydromorphone hydrochloride solutions
US9155734B2 (en) 2012-03-07 2015-10-13 Mallinckrodt Llc Stability of hydromorphone hydrochloride solutions

Also Published As

Publication number Publication date
WO2014137385A1 (en) 2014-09-12
CN105073095A (zh) 2015-11-18
MX2015011178A (es) 2015-11-30
IL240910A0 (en) 2015-10-29
US20150359790A1 (en) 2015-12-17
US9155734B2 (en) 2015-10-13
US10905685B2 (en) 2021-02-02
CA2902823C (en) 2019-06-11
JP6190475B2 (ja) 2017-08-30
US20130237558A1 (en) 2013-09-12
CA2902823A1 (en) 2014-09-12
JP2016510739A (ja) 2016-04-11
KR101892797B1 (ko) 2018-08-28
US20140005219A1 (en) 2014-01-02
EP2964188A1 (en) 2016-01-13
IL240910B (en) 2019-08-29
KR20150123804A (ko) 2015-11-04

Similar Documents

Publication Publication Date Title
CY1121928T1 (el) Φαρμακευτικη συνθεση υδροχλωρικης s-κεταμινης
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
BR112015021480A2 (pt) soluções de hidromorfona intratecais tendo estabi-lidade melhorada
UY35684A (es) Formulación de inhibidores de la tirosina quinasa de bazo (syk)
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
RS54873B1 (sr) Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
NI201500135A (es) Composición farmacéutica de hidrocloruro de s-ketamina
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
BR112016002459A2 (pt) Derivados de benzimidazolil-metil ureia como agonistas receptores de alx
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
BR112015019587A2 (pt) combinações compreendendo compostos maba e corticosteroides
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
EA201500931A1 (ru) Производные пиридин-4-ила
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112015024075A2 (pt) compostos de piridinilpirazoloquinolina
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
BR112017002675A2 (pt) métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila
BR112015032534A2 (pt) usos de composto ou de sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, composições farmacêuticas e métodos para prevenir e/ou tratar encefalopatia traumática crônica ou condição relacionada em indivíduo e para tratar indivíduo com lesão de concussão
BR112016015175A2 (pt) Formulação farmacêutica, método para a fabricação de uma formulação farmacêutica compreendendo sildenafila e clomipramina e comprimido

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: PIRAMAL CRITICAL CARE LIMITED (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.